Diagnostic testing guides 70% of health care decisions. Global testing volumes are rising due to an ageing population, the growing management of chronic diseases and increased access to care. At the same time, health systems are facing pressures to perform testing as efficiently as possible with limited staff and space while also reducing costs.
Many institutions and labs use multiple diagnostic platforms, often within a larger health care network. As they serve more patients and try to improve service levels with fewer qualified technicians, institutions are looking for new technologies that can help maximise testing efficiencies and help better manage resources.
Now Abbott announces the introduction of Alinity, its harmonised family of next-generation systems across immunoassay, clinical chemistry, point of care, haematology, blood and plasma screening and molecular diagnostics. Each Alinity platform will include a number of features to help institutions, clinicians and laboratorians better navigate through a pressure-packed healthcare environment.
Designed with universal, intuitive interfaces as well as common software and hardware, Abbott's Alinity systems will have the ability to work together, providing greater capacity and simplifying the user experience. Several of the platforms will be designed to run more tests in less space, generate test results faster and minimise human errors.